United States 
Canada
EU
UKWe’re proud to be part of such a tight-knit community. The more we can stay in touch, the closer we can work together. Click subscribe to receive news and updates about Amylyx.
Cerebrospinal Fluid Biomarker Effects and Target Engagement From a Fixed-Dose Combination of Sodium Phenylbutyrate and Taurursodiol in Alzheimer’s Disease: Results From the PEGASUS Trial
Lead Author: Steven E. Arnold, MD
Published: Clinical Trials on Alzheimer’s Disease (CTAD)
Date: December 3, 2022
Development of AMX0114, an Antisense Oligonucleotide Targeting Calpain-2
Lead Author: Mathias Leinders, PhD
Published: Society for Neuroscience (SfN)
Date: November 12 - 16, 2022
Real-World Strategies to Enhance the Palatability of Coformulated Sodium Phenylbutyrate and Taurursodiol for the Treatment of Amyotrophic Lateral Sclerosis
Lead Author: Nicole Shuckett, RD
Published: Northeast ALS Consortium Annual Meeting (NEALS)
Date: November 2, 2022
Development and Preclinical Assessment of AMX0114: an Antisense Oligonucleotide Targeting Calpain-2, a Critical Effector of Axonal Degeneration
Lead Author: Joshua Cohen, Co-CEO and Co-Founder, Amylyx Pharmaceuticals
Published: Northeast ALS Consortium Annual Meeting (NEALS)
Date: November 1, 2022
Reduced Plasma Concentration of the Neuroinflammation Biomarker Chitinase-3-Like Protein (CHI3L1/YKL-40) in the CENTAUR Trial
Lead Author: Robert Bowser, PhD
Published: Northeast ALS Consortium Annual Meeting (NEALS)
Date: November 1, 2022
International Phase 3 Trial Evaluating Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis (PHOENIX)
Lead Author: Leonard H. van den Berg, MD, PhD
Published: International Congress on Neuromuscular Diseases (ICNMD)
Date: July 9, 2022
Determining Individual Substantial Response in Amyotrophic Lateral Sclerosis: Utilizing a New Method on CENTAUR Trial Results
Lead Author: Tracey Jason, PhD, Head of Medical Affairs at Amylyx Pharmaceuticals Canada
Published: Canadian Neurological Sciences Federation (CNSF)
Date: June 26, 2022
Determining Individual Substantial Response in Amyotrophic Lateral Sclerosis: Utilizing a New Method on CENTAUR Trial Results
Lead Author: Lahar Mehta, MD, Head of Global Clinical Development at Amylyx Pharmaceuticals
Published: European Network to Cure ALS (ENCALS)
Date: June 2, 2022
Effect of Sodium Phenylbutyrate/Taurursodiol on Tracheostomy/Ventilation-Free Survival and Hospitalisation in Amyotrophic Lateral Sclerosis: Long-Term Results from the CENTAUR Trial
Lead Author: Sabrina Paganoni, MD, PhD
Published: Journal of Neurology, Neurosurgery and Psychiatry
Date: May 16, 2022
Survival Analyses from the CENTAUR Trial in Amyotrophic Lateral Sclerosis: Evaluating the Impact of Treatment Crossover on Outcomes
Lead Author: Sabrina Paganoni, MD, PhD
Published: Muscle & Nerve
Date: May 4, 2022